| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/1744666X.2015.1052795 |
| P698 | PubMed publication ID | 26048334 |
| P2093 | author name string | Juergen Braun | |
| Xenofon Baraliakos | |||
| Frank Heldmann | |||
| Uta Kiltz | |||
| Andrea Regel | |||
| Michael Sarholz | |||
| P2860 | cites work | Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 |
| 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis | Q24603648 | ||
| Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials | Q24619410 | ||
| Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q28218927 | ||
| Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention | Q29620087 | ||
| New population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination Survey | Q30586397 | ||
| Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug | Q32045021 | ||
| EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). | Q33260652 | ||
| Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials | Q33488444 | ||
| Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis | Q33910513 | ||
| Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis | Q33964496 | ||
| Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria | Q34055060 | ||
| American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee | Q34273218 | ||
| Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage | Q34387174 | ||
| Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis | Q34413304 | ||
| Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists | Q34476049 | ||
| Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study | Q34501045 | ||
| Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies | Q34505003 | ||
| Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey | Q34565551 | ||
| Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system | Q44398382 | ||
| Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness | Q44948656 | ||
| Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. | Q46016939 | ||
| Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy | Q46075190 | ||
| MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib | Q46295007 | ||
| Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept | Q46428495 | ||
| Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study | Q46428507 | ||
| Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial | Q46525954 | ||
| Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial | Q46665580 | ||
| Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration | Q47593985 | ||
| Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography | Q48008160 | ||
| ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. | Q49084708 | ||
| Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. | Q51455735 | ||
| The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. | Q51848128 | ||
| The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. | Q51848130 | ||
| Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. | Q51873041 | ||
| MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. | Q52887132 | ||
| Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. | Q52908636 | ||
| The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. | Q52911182 | ||
| Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. | Q52914494 | ||
| Radiologic diagnosis and pathology of the spondyloarthropathies. | Q52981134 | ||
| The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. | Q53163546 | ||
| Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. | Q53212276 | ||
| Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors | Q56974069 | ||
| Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo-controlled study | Q57673692 | ||
| Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis | Q58418172 | ||
| Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study | Q34580931 | ||
| Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. | Q34609572 | ||
| Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding | Q34617038 | ||
| Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis | Q34782199 | ||
| Predicting the outcome of ankylosing spondylitis therapy | Q34905433 | ||
| Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort | Q35165774 | ||
| Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management | Q35526652 | ||
| Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems | Q35554475 | ||
| Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system | Q35554631 | ||
| Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging | Q35555465 | ||
| Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? | Q35555802 | ||
| First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis | Q35636900 | ||
| Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. | Q35880376 | ||
| Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes | Q35954535 | ||
| Moving instead of asking? Performance-based tests and BASFI-questionnaire measure different aspects of physical function in ankylosing spondylitis | Q36245695 | ||
| Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion | Q36859283 | ||
| Imaging for the diagnosis and follow-up of ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion | Q36859877 | ||
| Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists | Q36932298 | ||
| Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists | Q37085249 | ||
| Variability in recommendations for total knee arthroplasty among rheumatologists and orthopedic surgeons | Q37431842 | ||
| Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 | Q37465467 | ||
| Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force | Q37465518 | ||
| Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy | Q37606758 | ||
| Tools for monitoring spondyloarthritis in clinical practice | Q37608920 | ||
| Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis | Q37723103 | ||
| The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. | Q37787639 | ||
| How to measure disease activity in axial spondyloarthritis? | Q37868909 | ||
| 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis | Q37871699 | ||
| The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis | Q38065934 | ||
| Adverse effects of TNF inhibitors in SpA: are they different from RA? | Q38285599 | ||
| Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases | Q38365041 | ||
| ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors | Q38491419 | ||
| The natural course of radiographic progression in ankylosing spondylitis--evidence for major individual variations in a large proportion of patients | Q39991059 | ||
| Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years | Q40031246 | ||
| Systematic skin cancer screening in Northern Germany | Q44369592 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ankylosing spondylitis | Q52849 |
| P1104 | number of pages | 12 | |
| P304 | page(s) | 935-946 | |
| P577 | publication date | 2015-06-05 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes | |
| P478 | volume | 11 |
| Q38631462 | An overview of investigational new drugs for treating ankylosing spondylitis |
| Q48641283 | Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis. |
| Q60910081 | Traditional Chinese medicine (TCM) collaborative care for patients with axial spondyloarthritis (AcuSpA): protocol for a pragmatic randomized controlled trial |
| Q97566271 | Validity and reliability of EQ-5D-5L among patients with axial spondyloarthritis in Singapore |
| Q39176611 | Validity and reliability of the Health Assessment Questionnaire among patients with spondyloarthritis in Singapore |
| Q39355454 | Validity and reliability of the Short Form 36 Health Surveys (SF-36) among patients with spondyloarthritis in Singapore |
Search more.